FDA Approves GSK's First-in-Class Anti-IL-5 Monoclonal Antibody Nucala for Eosinophilic COPD, Marking a New Era in Targeted Therapy

Chronic obstructive pulmonary disease (COPD), as the fourth leading cause of death globally, has consistently posed a severe threat to people's health. Recently, Nucala (mepolizumab), a "first-in-class" antibody therapy developed by global pharmaceutical giant GSK, received approval from the U.S. Food and Drug Administration (FDA) for use as an add-on maintenance treatment in adult COPD patients with poor disease control and elevated eosinophils. This undoubtedly brings a new opportunity for COPD treatment.

COPD: A Heavy Health Burden

COPD is a common chronic lung disease, with main symptoms including shortness of breath, chronic cough, sputum production, and reduced exercise tolerance. It is essentially caused by chronic inflammation, and the common pathological types are chronic bronchitis and emphysema. In advanced stages, patients experience limitations in daily life, require long-term oxygen therapy, and may develop severe conditions such as cor pulmonale and respiratory failure.

Data from the World Health Organization (WHO) shows that in 2021, approximately 3.5 million people globally died from COPD, accounting for about 5% of global deaths. It is projected that by 2050, the number of people with COPD worldwide will reach 592 million, a 23.3% increase from 2020. In China, the situation is equally severe. Research published in *BMC* indicates that the prevalence of COPD in the Chinese population aged 40 and above is 13.7%, with an estimated total of nearly 100 million patients. The disease has become the third leading cause of death in China. With the exacerbation of issues such as aging, the prevention and control of COPD are becoming increasingly urgent, highlighting the pressing need for early screening and personalized treatment strategies.

Current Treatment Dilemma

COPD is an irreversible disease with high treatment difficulty. The current standard triple therapy (fixed-dose combination of ICS, LABA, and LAMA) used in clinical practice can help patients alleviate symptoms. However, even with the use of inhaled triple therapy, a significant proportion of patients continue to experience persistent symptoms, and their condition may still progress. Studies show that about 40% of COPD patients exhibit type 2 inflammation characteristics, marked by elevated peripheral blood eosinophil counts (BEC). In the United States, approximately 70% of COPD patients continue to have symptoms after receiving triple therapy, among whom the blood eosinophil count reaches or exceeds 150 cells/μL.

Nucala: A New Hope for Treatment

Nucala is a monoclonal antibody targeting interleukin-5 (IL-5), a key cytokine in type 2 inflammation. It was initially approved in the United States in 2015 for the treatment of severe asthma with an eosinophilic phenotype and has since been used to treat a range of IL-5 mediated diseases associated with type 2 inflammation. This approval successfully expands its indications, offering a new treatment option for COPD patients with baseline blood eosinophil counts of 150 cells/μL.

FDA Approval Based on Positive Results from Two Phase III Clinical Trials — MATINEE and METREX. The studies showed that Nucala reduced the annualized rate of moderate to severe exacerbations by 21% across all study populations, by 31% in patients with moderate to severe chronic bronchitis only, and lowered the annualized rate of exacerbations leading to emergency department visits or hospitalizations by 35%. COPD-related hospitalizations have become a significant challenge for healthcare systems globally and are expected to be one of the leading causes of hospitalization. The ability of Nucala to reduce hospitalization rates is of great significance.

Dr. Jean Wright, CEO of the Chronic Obstructive Pulmonary Disease Foundation, stated: "COPD is not just a disease, but an ongoing cycle. Biologics like Nucala offer a new direction for those affected by COPD." Kaivan Khavandi, Global Head of Respiratory R&D at GSK, also commented: "The approval of Nucala provides an important option for patients with COPD. Particularly for those with the eosinophilic phenotype, Nucala brings renewed hope for improved care."

The approval of Nucala marks a new era in the treatment of COPD with targeted biologics, effectively advancing the individualization and refinement of disease management, and bringing new hope to many patients with COPD.

Disclaimer: This article aims to promote communication and exchange in pharmaceutical academia and is intended for healthcare professionals only. MedSci Medicine does not recommend any drugs and/or indications. The drug information involved in this article is for reference only and cannot replace professional medical guidance in any way, nor should it be regarded as diagnostic or therapeutic advice. If you want to know specific disease diagnosis and treatment information, please follow the opinions or instructions of hospital doctors.